MedTrace Logo

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

NCT05833906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-01-19

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of CKR-051 in healthy participants.

This study aiming to develop an agent for skin regeneration; potential treatments include acute and chronic wounds (c.f. Diabetic foot ulcers).

Conditions

  • Healthy

Interventions

DRUG

CKR-051 Dose 1

Subjects will be administered 5 g of CKR-051.

DRUG

CKR-051 Dose 2

Subjects will be administered 10 g of CKR-051.

DRUG

CKR-051 Dose 3

Subjects will be administered 10 g of CKR-051.

DRUG

CKR-051 Dose 4

Subjects will be administered 10 g of CKR-051.

DRUG

Placebo

Placebo comparator.

Sponsors & Collaborators

  • CK Regeon Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2024-01-08
Completion
2024-01-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833906 on ClinicalTrials.gov